MaxOvary
Non-invasive Solutions for PCOS
Company Overview
Snapshot
Founded in January 2023 by Eytan Frey, MaxOvary operated with 1–10 employees. The company secured one disclosed funding round from one investor, Cactus Capital, in January 2023.
Business overview
MaxOvary is a Health Tech & Life Sciences company focused on developing non-invasive solutions for gynecological diseases, specifically addressing Polycystic Ovary Syndrome (PCOS). The company's core technology involves a transducer designed for innovative, breakthrough, and disposable treatments. MaxOvary aims to provide an alternative to conventional treatments for women experiencing difficulties with pregnancy, which often involve physical and mental suffering and offer only temporary solutions. The company operates within the medical devices sector, targeting the healthcare and life sciences industries, particularly healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is MaxOvary's primary focus?
- MaxOvary is developing non-invasive solutions for gynecological diseases, specifically focusing on Polycystic Ovary Syndrome (PCOS).
- When was MaxOvary founded?
- MaxOvary was founded in January 2023.
- Who is a co-founder of MaxOvary?
- Eytan Frey is a co-founder and CEO of MaxOvary.
- What is the status of MaxOvary?
- MaxOvary is non-active and ceased to operate in December 2024.